International Journal of Hematology

, Volume 109, Issue 6, pp 650–656 | Cite as

Hemostatic assessment of combined anticoagulant therapy using warfarin and prothrombin complex concentrates in a case of severe protein C deficiency

  • Kenichi Ogiwara
  • Keiji NogamiEmail author
  • Kuniyoshi Mizumachi
  • Takashi Nakagawa
  • Nozomi Noda
  • Shouichi Ohga
  • Midori Shima
Original Article


Patients with severe congenital protein (P)C deficiency require long-term anticoagulant management. Recombinant PC concentrates for prophylactic use are not available in Japan; prothrombin complex concentrates (PCC), containing factors (F)II, VII, IX, X, and PC (PPSB-HT®), have been used ‘off-label’ in a few patients. We investigated the combined use of prophylactic PCC and Warfarin (VKA; PT-INR 2.0–2.5) in a severely PC-deficient patient in whom VKA alone did not prevent recurrent purpura. Plasma VKA-dependent factor levels and global PC function (Thrombopath®) were assessed. Plasma activity levels of FII/FVII/FIX/FX post-infusion of PCC (6.3 unit/kg) increased 35/27/27/35 (initial level) to 59/60/38/83 IU/dl, respectively. FVII:C and FIX:C rapidly returned to baseline levels 12–24 h post-infusion, but FII:C and FX:C returned more slowly. PC antigen (< 5%) increased to ~ 15%, followed by return to baseline levels 24 h post-infusion. Global PC function was very low (%PiCi 24%), but improved post-PCC infusion. This potential was slightly detectable even at an undetectable PC level. At day 3, high levels of d-dimer and FDP were observed without thrombotic event, but these improved post-infusion. Although PCC restored VKA-dependent coagulation factors, PC contained in PCC significantly improved global anticoagulation, and was clinically beneficial in this severely deficient patient.


PC deficiency PCC Warfarin Vitamin K-dependent clotting factor PC pathway function 



We thank Dr. Satoshi Mushiake for providing patient’s lab data, and thank patient’s home doctor for keeping the patient’s condition stable for long term. This work was partly supported by a Grant-in-Aid for Scientific Research (KAKENHI) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) to KN (Grant No. 18K07885) and by a Japan Agency for Medical Research and Development (AMED) to KN (18ek0109210h0002).

Author contributions

KO; performed experiments, interpreted the data, made the figures, and wrote the paper, KN; designed the research, interpreted the data, wrote the paper, edited the manuscript, and approved the final version to be published, KM, TN; performed experiments, NN, SO, performed the genetic analyses and interpreted the data, MS; supervised the studies.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Ohga S, Kang D, Kinjo T, Ochiai M, Doi T, Ishimura M, et al. Paediatric presentation and outcome of congenital protein C deficiency in Japan. Haemophilia. 2013;19:378–84.CrossRefGoogle Scholar
  2. 2.
    Goldenberg NA, Manco-Johnson MJ. Protein C deficiency. Haemophilia. 2008;14:1214–21.CrossRefGoogle Scholar
  3. 3.
    Ishiguro A, Ezinne CC, Michihata N, Nakadate H, Manabe A, Taki M, et al. Pediatric thromboembolism: a national survey in Japan. Int J Hematol. 2017;105:52–8.CrossRefGoogle Scholar
  4. 4.
    Monagle P, Chan AKC, Goldenberg NA, Ichord RN, Journeycake JM, Nowak-Göttl U, et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e737S–801S.CrossRefGoogle Scholar
  5. 5.
    Oka T, Suzuki Y, Hiramoto A, Azuma H, Okuno A, Yoshioka H, et al. Severe heterozygous protein C deficiency with relapsing purpura fulminans from the newborn period. Rinsho Ketsueki. 1986;27:1971–6 (Article in Japanese).Google Scholar
  6. 6.
    Yasaka M, Sakata T, Minematsu K, Naritomi H. Correction of INR by prothrombin complex concentrate and vitamin K in patients with warfarin related hemorrhagic complication. Thromb Res. 2002;108:25–30.CrossRefGoogle Scholar
  7. 7.
    Lisman T, Porte RJ. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. Blood. 2010;116:878–85.CrossRefGoogle Scholar
  8. 8.
    Toulon P, Smirnov M, Triscott M, Safa O, Biguzzi E, Bouziane K, et al. A new chromogenic assay (HemosIL ThromboPath) is sensitive to major prothrombotic risk factors affecting the protein C pathway. Results of a multicenter study. Thromb Res. 2009;124:137–43.CrossRefGoogle Scholar
  9. 9.
    Shen L, Dahlbäck B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa. J Biol Chem. 1994;269:18735–8.Google Scholar
  10. 10.
    Dahlbäck B. Pro- and anticoagulant properties of factor V in pathogenesis of thrombosis and bleeding disorders. Int J Lab Hematol. 2016;38(Suppl 1):4–11.CrossRefGoogle Scholar
  11. 11.
    Koenen RR, Tans G, van Oerle R, Hamulyak K, Roseng J, Hackeng TM. The APC-independent anticoagulant activity of protein S in plasma is decreased by elevated prothrombin levels due to the prothrombin G20210A mutation. Blood. 2003;102:1686–92.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Hematology 2019

Authors and Affiliations

  • Kenichi Ogiwara
    • 1
  • Keiji Nogami
    • 1
    Email author
  • Kuniyoshi Mizumachi
    • 1
  • Takashi Nakagawa
    • 1
  • Nozomi Noda
    • 2
  • Shouichi Ohga
    • 3
  • Midori Shima
    • 1
  1. 1.Department of PediatricsNara Medical UniversityKashiharaJapan
  2. 2.Department of Clinical Chemistry and Laboratory MedicineKyushu University HospitalFukuokaJapan
  3. 3.Department of PediatricsKyushu University HospitalFukuokaJapan

Personalised recommendations